| COVAXIN |
BBV152[8] |
Bharat Biotech,ICMR[8][9] |
Inactivated Virus [5][8] |
INDIA[8] |
https://drive.google.com/file/d/1W26f8M-yS41On5BdW8BvV9fX7bV-TGBj/view?usp=sharing |
India, Iran, Nepal, Brazil, Mayanmar, Vietnam, Sri lanka[9] |
Complete[8] |
20 |
6 months |
6µg of whole-virion inactivated SARSCoV-2 antigen (Strain: NIV-2020-770), and the other inactive ingredients such as aluminum hydroxidegel (250 µg), TLR 7/8 agonist (imidazoquinolinone) 15 µg, 2-phenoxyethanol 2.5 mg, and phosphatebuffer saline up to 0.5 ml. The vaccine (COVAXIN ) thus has been developed by using inactivated/killedvirus along with the aforementioned chemicals |
3 µg/dose- 4 weeks apart[8] |
2, 28 days apart[9] |
2-8 degree C[4][8][10] |
81%[9][10] |
Deltoid muscle of the upper arm |
25800[8] |
Injection site pain , Swelling , Redness , Itching, Headache, Fever, Malaise/body ache, Nausea, Vomiting, Rashes [30] |
Pain at injection site was reported by a few participants(5%). One participant who received the control reported swelling. The events observed, however, were mild or moderate in severity. The adverse effects occured more frequently after the first dose than the second dose. [40] |
Some commonn systemic adverse events such as headache (3%), fever (2%), fatigue(3%), nausea and vomiting(2%). Almost all of the adverse events were mild or moderate in severity and were more frequently observed after the first dose. All adverse events resolved within a day. No significant differences were observed between the vaccinated and the control group. [40] |
Effective (Data not available)[15], [21] |
NA |
NA |
Effective (Data not available)[15], [21] |
| COVISHEILD / ASTRAZENCA |
Vaxzevria, ChAdOx1 nCoV-19 and AZD1222 [8] |
BARDA, OWS, SII[10] |
Non-replicating viral vector[5][8] |
UK |
USA, India, Africa, Australia, Moscow, Malysia, Singapore.[11] |
Andorra, Argentina, Bahrain, Bangladesh, Barbados, Brazil, Canada, Chile, Colombia, Dominican Republic, Ecuador, Egypt, El Salvador, Ethiopia, European Union, Faroe Islands, Gambia, Ghana, Greenland, Guyana, Hungary, Iceland, India, Indonesia, Iraq, Ivory Coast, Kenya, Lesotho, Malawi, Malaysia, Maldives, Mauritius, Mexico, Morocco, Myanmar, Nepal, Nigeria, Norway, Pakistan, Philippines, Rwanda, Saint Vincent and the Grenadines, Serbia, Sierra Leone, South Korea, Sri Lanka, Sudan, Suriname, Taiwan, Thailand, Uganda, UK, Vietnam, WHO[5][8] |
Complete[8][14] |
3009 |
6 months |
L-Histidine, L-Histidine hydrochloride monohydrate, Magnesium chloride hexahydrate,Polysorbate 80, Ethanol, Sucrose, Sodium chloride, Disodium edetate dihydrate (EDTA), Water forinjection. |
0.5 ml/dose- 4 to 6 weeks apart |
2, three months apart [5] |
2-8 degree C for 30 days-20 degrees for 6 monthsRoom Temperature for 12 hrs[4] |
62% [5] |
Intramuscular injection in the deltoid muscle of the upper arm |
30000[8] |
Tenderness, pain, warmth, redness, itching, swelling or bruising at the injection site, all of which generally resolve within a day or two. [33][8] |
The local and systemic reactions were commonly seen in participants who received the ChAdOx1 nCoV-19 vaccine when compared to the control vaccine group. The most commonly reported local reactions were injection-site pain and tenderness which occurred mostly within 48 hours post vaccination. Atleast one local reaction was reported by 43 (88%) of 49 participants in the 18-55 years group, 22 (73%) of 30 in the 56-69 years group, and 30 (61%) of 49 in the 70 years and older group who received the vaccine. After the booster dose, similar proportions of local symptoms were reported after the boost vaccination with the standard dose of ChAdOx1 nCoV-19, with 37 (76%) of 49 participants in the 18-55 years group, 21 (72%) of 29 in the 56-69 years group, and 27 (55%) of 49 in the 70 years and older group. A similar patter was observed in all age groups in participants after the first and second vaccination of low dose vaccine. In the two-dose control group, local symptoms were reported by 33 (57%) of 58 participants in the 18-55 years group, five (25%) of 20 in the 56-69 years group, and seven (35%) of 20 in the 70 years and older group after the prime vaccination and by 50 (86%) of 58 in the 18-55 years group, seven (37%) of 19 in the 56-69 years group, and four (20%) of 20 in the 70 years and older group after the booster dose. [23] |
The most commonly reported sysytemic reactions were fatigue, headache, feverishness and myalgia. After the first vaccination with the standard dose, atleast one systemic symptom was reported by 42 (89%) of the 18-55 years group, 23 (77%) in 56-69 years group and 32 (65%) in the 70 years and older group. After the booster dose, at least one systemic adverse reaction was reported by 32 (65%) in the 18-55 years age group, 21 (72%) in the 56-69 age group and 21 (43%) in the 70 years and older group. A similar pattern of decreased reactogenicity with increasing age was observed in the low dose group. [23] |
70.4% [15] |
10.4% [20] |
NA |
97% [35] |
| MODERNA |
mRNA-1273 |
Moderna, BRADA,NIAID |
m-RNA Vaccine[5][8] |
US |
US, Switzerland[11] |
Andorra, Canada, European Union, Faroe Islands, Greenland, Iceland, Israel, Liechtenstein, Norway, Qatar, Saint Vincent and the Grenadines, Singapore, Switzerland, United Kingdom, United States, Vietnam |
III[8] |
816 |
12hrs-6 months |
messenger ribonucleic acid(mRNA), lipids (SM-102, polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG],cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC]), tromethamine,tromethamine hydrochloride, acetic acid, sodium acetate trihydrate, and sucrose |
100µg/dose -4 weeks apart |
2, 28 days apart [5] |
-20 degree C for upto 6 months; 2-8 degree C upto 30 days, Room temperature for 12 hrs[4] |
86.4% - 94.1%[5] |
Intramuscular injection in the deltoid muscle of the upper arm |
30000 |
chills, headache, pain, tiredness, and/or redness and swelling at the injection site, all of which generally resolve within a day or two. On rare occasions, mRNA vaccines have appeared to trigger anaphylaxis, a severe reaction that is treatable with epinephrine (the drug in Epipens®). For that reason, the CDC requires vaccination sites to monitor everyone for 15 minutes after their COVID-19 shot, and for 30 minutes if they have a history of severe allergies.[29] |
Local adverse reactions at the injection site were reported by participants who received the vaccine than those who received the placebo after both the first dose ((84.2%, vs. 19.8%) and the second dose (88.6%, vs. 18.8%). Most of these reactions resolved within a day or two. The most commonly reported injection site reactions was pain. Other reactions were erythema, induration, and tenderness, and they resolved over the following 4 to 5 days. The local adverse reactions were more common among the younger participants (18-<65 years) than among older participants. [24] |
Systemic adverese events were reported mostly by the participants who received the vaccine when compared to the placebo group (54.9%, vs. 42.2% after the first dose and 79.4%, vs. 36.5% after the second dose). The systemic adverse reactions were more common among the younger participants (18-<65 years) than among older participants. The adverse events were less common in pariticpants with baseline SARS-CoV-2 infection when compared to participants who were negative at baseline. [24] |
Similar efficacy as original virus [18] |
Reduced antibody levels [18] |
NA |
Effective (Data not available) [17] |
| COMIRNATY |
mRNA - BNT162b2 |
Pfizer, BioNTech; Fosun Pharma[5] |
m-RNA Vaccine[5][8] |
MULTINATIONAL |
Germany, US, UK, India, China[11] |
Albania, Andorra, Argentina, Aruba, Australia, Bahrain, Brazil, Canada, Caribbean, Chile, Colombia, Costa Rica, Ecuador, European Union, Faroe Islands, Greenland, Hong Kong, Iceland, Iraq, Israel, Japan, Jordan, Kuwait, Lebanon, Liechtenstein, Malaysia, Mexico, Monaco, New Zealand, North Macedonia, Norway, Oman, Panama, Philippines, Qatar, Rwanda, Saint Vincent and the Grenadines, Saudi Arabia, Serbia, Singapore, South Africa, South Korea, Suriname, Switzerland, UAE, UK, US, Vatican City, WHO |
III[8] |
1220 |
6 months |
mRNA,lipids ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 2[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, 1,2-Distearoyl-sn-glycero-3-phosphocholine, and cholesterol), potassium chloride, monobasic potassiumphosphate, sodium chloride, dibasic sodium phosphate dihydrate, and sucrose. |
30µg/dose -3 weeks apart |
2, 21 days apart [5] |
-70 degree C upto 6 months2-8 degree C upto5 days[4][12] |
52% after first dose and 95% after second dose.[5][8] |
Intramuscular injection in the deltoid muscle of the upper arm[12] |
43448[8] |
Chills, headache, pain, tiredness, and/or redness and swelling at the injection site, all of which generally resolve within a day or two of rest, hydration, and medications like acetaminophen. (If symptoms don't resolve within 72 hours or if you have respiratory symptoms, such as cough or shortness of breath, call your doctor.) On rare occasions (as in, 11 cases in 18 million vaccinations), mRNA vaccines have appeared to trigger anaphylaxis, a severe reaction that is treatable with epinephrine (the drug in Epipens®). For that reason, the Centers for Disease Control and Prevention (CDC) requires vaccination sites to monitor everyone for 15 minutes after their COVID-19 shot, and for 30 minutes if they have a history of severe allergies or are taking a blood thinner.[32] |
Majority of the participants who received the vaccine reported local adeverse events compared to the placebo group. Among the vaccine recepients, mild to moderate pain at the injection site within 7 days was reported was the most common local reaction with 1% of participants across all age groups reporting severe pain. The older participants (55 years and older) reported pain at injection site less frequently (71% after first dose and 66% after second dose) when compared to the younger participants (83% after first dose and 78% after second dose). Vey few participants reported redness or swelling at injection site. Most local reactions resolved within a day or two. [25] |
Systemic events such as fever and chills were reported within 1-2 days after vaccination and resolved son after. Majority of the young vaccine recipients (16-55 years) reported systemic reactions when compared to older participants (above 55 years) mostly after the second dose than the first dose. After the second dose, 59% reported fatigue, 52% reported headache amongst the young participants compared to 51% (fatigue) and 39% (headache) amongst the older recipients. In the placebo group, 23% and 24% of the younger particpants reported fatigue and headache respectively after the second dose. Fever was reported by 16% of younger participants and 11% of particpants after the second dose. 0.2% of vaccine recipients and 0.1% of placebo recipients reported fever (temperature, 38.9 to 40°C) after the first dose, as compared with 0.8% and 0.1%, respectively, after the second dose. Lymphadenopathy was reported in 64 (0.3%) vaccine recipients and 6 (<0.1%) placebo recipients. No COVID-19 related deaths were observed. [25] |
89.5% after 2 doses [16] |
75% [16] |
Similar efficacy as original virus [18] |
Effective (Data not available) [17] |
| SPUTNIK V |
Gam-COVID-Vac[8] |
Gamaleya Research Institute, Acellena Contract Drug Research and Development[8][10] |
Non-replicating viral vector[8] |
RUSSIA |
US, South Korea, Russia, Tibet[11] |
Algeria, Angola, Argentina, Armenia, Azerbaijan, Bahrain, Belarus, Bolivia, Congo, Djibouti, Egypt, Gabon, Ghana, Guatemala, Guinea, Guyana, Honduras, Hungary, Iran, Iraq, Jordan, Kazakhstan, Kenya, Kyrgyzstan, Laos, Lebanon, Mexico, Moldova, Mongolia, Montenegro, Morocco, Myanmar, Namibia, Nicaragua, North Macedonia, Pakistan, Palestine, Paraguay, Republika Srpska, Russia, Saint Vincent and the Grenadines, San Marino, Serbia, Slovakia, Sri Lanka, Syria, Tunisia, Turkmenistan, United Arab Emirates, Uzbekistan, Venezuela, Zimbabwe[10] |
Complete[8] |
765 |
2 months |
Tris-(hydroxymethyl)-aminomethane, Sodium chloride, Sucrose, Magnesium chloride hexahydrate, Disodium EDTA dihydrate, Polysorbate 80, Ethanol, and Water. |
0.5ml/dose- 3 weeks apart |
2, 21 days apart[10] |
1. Frozen (-18 degree C) 2.Lyophilisied (2-8 degree C)[4][10] |
91.4%[8] |
intramuscular injection in the deltoid muscle of the upper arm |
22714[8] |
|
|
|
|
Effective [38] |
|
Effective [39] |
| JANSSEN |
JNJ-78436735/Ad26.COV2.S[8] |
Johnson & Johnson[5] |
Non-replicating viral vector[5][8] |
NETHERLANDS + US |
UK, US[11] |
Andorra, Bahrain, Canada, European Union, Faroe Islands, Greenland, Iceland, Liechtenstein, Norway, Saint Vincent and the Grenadines, Switzerland, US, WHO |
Interim III[8] |
368 |
Is different for different batches |
recombinant,replication-incompetent adenovirus type 26 expressing the SARS-CoV-2 spike protein, citric acidmonohydrate, trisodium citrate dihydrate, ethanol, 2-hydroxypropyl-β-cyclodextrin (HBCD),polysorbate-80, sodium chloride |
0.5*10^11 vp[31] |
1[5][31] |
2-8 degree C[4][31] |
72%[5] |
Intramuscular injection in the deltoid muscle of the upper arm |
60000[8] |
Fatigue, fever headache, injection site pain, or myalgia (pain in a muscle or group of muscles), all of which generally resolve within a day or two. It has had noticeably milder side effects than the Pfizer and Moderna vaccines, according to the FDA report released in late February. No one suffered an allergic reaction in clinical trials for the vaccine, according to the company.[31] |
|
|
|
52% (South African study) [19] |
Reduced efficacy [18] |
|
| CORONAVAC |
|
Sinovac[8] |
Inactivated vaccine (formalin with alum adjuvant)[8] |
CHINA |
China, Brazil[8][11] |
Azerbaijan, Bolivia, Brazil, Cambodia, China, Chile, Colombia, Dominican Republic, Ecuador, Hong Kong, Indonesia, Laos, Malaysia, Mexico, Paraguay, Philippines, Thailand, Tunisia, Turkey, Ukraine, Uruguay, Zimbabwe |
III[8] |
367 |
12 months |
Inactivated SARS-CoV-2 virus, aluminium hydroxide, disodium hydrogen phosphate dodecahydrate, sodium dihydrogen phosphate monohydrate, sodium chloride. |
3µg/dose- 2 weeks apart |
2[4][8] |
2-8 degree C[4] |
50.4%[4] |
Intramuscular injection in the deltoid muscle of the upper arm |
8870[8] |
injection site pain, nausea, diarrehea,headache,fatigue,myalgia,cough,sore throat and abdominal pain[28] |
|
|
Effective [36] |
Reduced efficacy [36] |
Reduced efficacy [36] |
|
| BBIBP-CorV |
|
Beijing Institute of Biotechnology/ China National Biotech Group-Sinopharm[8] |
Inactivated virus[8] |
CHINA |
China[11] |
Afghanistan, Algeria, Argentina, Bahrain, Bolivia, Cambodia, China, Egypt, Equatorial Guinea, Gabon, Guyana, Hungary, Iraq, Jordan, Kyrgyzstan, Laos, Macau, Maldives, Mongolia, Morocco, Mozambique, Namibia, Nepal, Pakistan, Peru, Senegal, Serbia, Seychelles, Sierra Leone, Sri Lanka, UAE, Venezuela, Zimbabwe |
III On-going[8] |
230 |
24 months |
inactivatedSARS-CoV-2, strainHB02,Disodium hydrogen phosphate,sodium chloride, sodium dihydrogen phosphate, aluminumhydroxide |
4µg/dose - 3 weeks apart |
2[4] |
2-8 degree C[4] |
79.34%[4][8] |
intramuscular injection in the deltoid muscle of the upper arm |
Phase 1 - 192Phase 2 - 448[8] |
pain at the injection site,headache, and fatigue; Serious Adverse Events assessed to be possibly linked to vaccination: (serious nausea andinflammatory demyelination syndrome/acute disseminated encephalomyelitis)[34] |
Out of the 144 vaccine recipients, 42 (29%) of them had atleast one adverse reaction within a week after vaccination compared to 8 (17%) of placebo recipients. Within a week of vaccination in the 18-59 years grroup, 11 (46%) of the recipients in the 2 Όg cohort (compared with three [38%] of eight placebo recipients; p>0·99), eight (33%) of 24 vaccine recipients in the 4 Όg cohort (compared with two [25%] of eight placebo recipients; p>0·99), and 11 (46%) of 24 vaccine recipients in the 8 Όg cohort (compared with one [13%] of eight placebo recipients; p=0·2) reported atleast one adverse event. In the 60 years and older group, atleast (4%) of 24 vaccine recipients in the 2 Όg cohort (compared with one [13%] of eight placebo recipients; p=0·44), six (25%) of 24 vaccine recipients in the 4 Όg cohort (compared with zero placebo recipients; p=0·3), and five (21%) of 24 vaccine recipients in the 8 Όg cohort (compared with one [13%] of eight placebo recipients; p>0·99) reported one adverse events. The most common adverse event reported was pain at the injection site, reported by 24% of vaccine recipient compared to 6% of placebo recipient. [26] |
Fever was the most common systemic adverse event reported in 4% of vaccine recipients and 6% of placebo recipients. Fever was reported In all 3 cohorts of the 18-59 age group,one (4%) of 24 in the 2 ÎŒg cohort, one (4%) of 24 in the 4 ÎŒg cohort, and two (8%) of 24 in the 8 ÎŒg cohort. Other systemic adverese events were fatigue, inappetance, nausea, constipation, headache, vomiting and itch. All adverese evets were mild to moderate in severity and no adverse events were reported 28 days after vaccination. [26] |
|
|
|
|
| EpiVacCarona |
|
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology[7] |
Peptide Vaccine |
RUSSIA |
Russia[7] |
Russia, Turkmenistan |
III[6] |
no data found |
|
|
no data found |
2, interval of 21 to 28 days[7] |
no data found |
100% claimed in Russia |
Intramuscular[7] |
40,000 [7] |
|
|
|
|
|
|
|
| COVIDICEA |
Ad5-nCoV [8] |
CanSino Biologics[4] |
Replication-defective Viral vector vaccine[8] |
CHINA |
China |
China, Hungary, Mexico, Pakistan, Chile |
III[8] |
no data found |
12 months at -70 degree C |
replication-deficientAd type 5 vectorexpressing full-lengthspike protein |
0.5 *10^11 vp |
1[4] |
2-8 degree C[4] |
0.657 |
intramuscular injection in the deltoid muscle of the upper arm |
40000 |
|
|
|
|
|
|
|
| COVIVAC |
|
Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products |
Inactivated virus |
RUSSIA |
Russia |
China, Uzbekistan |
III |
no data found |
|
SARS-CoV-2 strain AYDAR-1 antigen inactivated by inactivated by beta-propiolactone with 0.3-0.5 mg aluminium hydroxide, 0.5ml or less phosphate buffer solution. |
0.5ml/dose, 14 days apart |
2 |
2-8 degree C |
0.5039 |
|
|
|
|
|
|
|
|
|
| NOVAVAX |
NVX-CoV2373, Covovax, TAK-019 |
Serum Institute of India |
Protien subunit vaccine[5][8] |
GREAT BRITAIN(Maryland) [8] |
USA, UK, Japan, Singapore, Spain, Mexico[5][11] |
Britain, South Africa |
South Africa - IIb USA and UK - III[8] |
1404 |
|
full-length spike (S) protein nanoparticle of the SARS-CoV-2 virus, Matrix-Mâ¢, |
5µg SARS-CoV-2 rS+ 50µg Matrix-M1 adjuvant- 3 weeks apart |
2, one month apart[5] |
2-8 degree C[5] |
89.3%[5] |
intramuscular injection in the deltoid muscle of the upper arm |
45000[8] |
While the Novavax vaccine is still being studied, early trials have shown no adverse events.[27] |
No serious adverese events or reactions were reported in either the group that received the vaccine alone or vaccine with adjuant. After the first vaccination, local adverse events were mild or absent. A few participants who received the vaccination reported headache, fever or malaise. After the second vaccination dose, local adverse reactions were mild or absent. The mean duration of local reactions was 2 days or less in both the first and second vaccination periods. [37] |
Laboratory abnormalities (reduced hemoglobin, elevated liver enzymes) were reported in 13 participants (10%)-9 after the first dose of vaccination and after the second dose. These abnormalities were not assciated with any clinical manifestations and did not worsen on repeat vaccination. [37] |
|
|
|
|
| VAT00008 |
|
Glaxo Smithkline and Sanofi[8] |
Protien subunit vaccine[8] |
France and Great Britain |
|
|
I/II[8] |
|
|
|
|
|
|
|
|
440[8] |
|
|
|
|
|
|
|
| ZyCov-Di[10] |
|
Zydus Cadilla |
DNA vaccine |
India |
India[11] |
|
III on-going |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| INO-4800 |
|
Inovio/International Vaccine Institute |
DNA vaccine |
|
|
|
II/III[8] |
|
|
|
1.0 - 2.0 mg with interval of 4 weeks[8] |
2[8] |
|
78% for 1.0mg84% for 2.0mg[8] |
|
6178[8] |
|
|
|
|
|
|
|
| ZF2001 |
|
Anhui Zhifei Longcom Biopharmaceutical/Chinese Academy of Medical Sciences |
Protein Subunit Vaccine |
China and Uzbekistan |
|
|
III On-going[8] |
|
|
|
|
|
|
|
|
900[8] |
|
|
|
|
|
|
|
| CoVLP |
|
Medicago |
Protein Subunit Vaccine |
|
|
|
II/III[8] |
|
|
|
3.75 µg with difference of 3 weeks.[8] |
2[8] |
|
|
|
30,612[8] |
|
|
|
|
|
|
|
| HGCO19[10] |
|
Pune based Genova and Seattle-based HDT BioTech Corporation. |
mRNA vaccine |
India |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|